ASCO & Member News
Find highlights of ASCO initiatives, including news related to oncology research and clinical practice, policy and advocacy, education, and meetings, and updates on ASCO’s patient-centered site, Cancer.Net, and Conquer Cancer, the ASCO Foundation.
Member News provides updates on ASCO member career news, awards, and recognitions, as well as profiles of ASCO volunteer leaders. If you have news you would like to share, please contact ascoconnection@asco.org.
Feb 04, 2020
The report catalogs a year’s worth of remarkable research advancements, reinforces the need for sustained federal research funding, and details other major trends in oncology.
Jan 30, 2020
ASCO and ABIM have spent the past several years collaborating on an alternative assessment pathway for oncology specialists, and the organizations are pleased to launch the Medical Oncology: Learning & Assessment program this year.
Jan 10, 2020
The new course collection offers participants an opportunity to learn about and engage with a topic that historically has low rates of familiarity among clinicians.
Jan 10, 2020
Dr. Nathan Pennell, of the Cleveland Clinic, discusses his work hosting ASCO’s JCO Oncology Practice (JCO OP) podcast.
Jan 10, 2020
Find out what your fellow ASCO members have been up to in this month's edition of Member News.
Dec 17, 2019
Six New Members Elected to ASCO Board of Directors and Nominating Committee
Nov 26, 2019
ASCO's oncology-specific model is uniquely positioned to confront care delivery challenges in an increasingly complex medical specialty and addresses an array of pressures facing cancer care.
Nov 12, 2019
Organizations with the 501(c)(6) tax-exemption have increased flexibility in how they can advocate for issues on behalf of their members.
Nov 05, 2019
Driven by evidence and uniquely suited to physician and patient needs, ASCO’s comprehensive clinical affairs programs help practices successfully navigate the changing health care delivery system.
Oct 28, 2019
ASCO developed a Decision Aid to assist physician-investigators and research staff in determining whether an adverse event should be reported to the sponsor as an SAE and attributed to the investigational drug.